XEJ Stock Overview
Designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Accuray Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.59 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$1.27 |
| Beta | 1.4 |
| 11 Month Change | 0.63% |
| 3 Month Change | 19.55% |
| 1 Year Change | -37.89% |
| 33 Year Change | -66.88% |
| 5 Year Change | -36.40% |
| Change since IPO | -92.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| XEJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -3.6% | -2.2% |
| 1Y | -37.9% | -3.5% | 13.3% |
Return vs Industry: XEJ underperformed the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: XEJ underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| XEJ volatility | |
|---|---|
| XEJ Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XEJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XEJ's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 987 | Suzanne Winter | www.accuray.com |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Accuray Incorporated Fundamentals Summary
| XEJ fundamental statistics | |
|---|---|
| Market cap | €161.34m |
| Earnings (TTM) | -€14.29m |
| Revenue (TTM) | €410.56m |
0.4x
P/S Ratio-11.6x
P/E RatioIs XEJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XEJ income statement (TTM) | |
|---|---|
| Revenue | US$446.55m |
| Cost of Revenue | US$303.43m |
| Gross Profit | US$143.12m |
| Other Expenses | US$158.67m |
| Earnings | -US$15.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 32.05% |
| Net Profit Margin | -3.48% |
| Debt/Equity Ratio | 381.9% |
How did XEJ perform over the long term?
See historical performance and comparison